Pulse Biosciences Newsroom

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires15:48 ET

Sector Update: Health Care

MT Newswires15:14 ET

Pulse Biosciences Stock Rises; Co-Chairman Duggan May Buy Shares

MT Newswires14:47 ET

Pulse Biosciences, Inc.'s (NASDAQ:PLSE) Largest Shareholder, Top Key Executive Robert Duggan Sees Holdings Value Fall by 4.8% Following Recent Drop

Simply Wall StNov 15 07:04 ET

12 Health Care Stocks Moving In Friday's Intraday Session

BenzingaNov 1 12:36 ET

Pulse Biosciences New Treatment Study Shows Reduction of Benign Thyroid Nodules

MT NewswiresOct 31 15:24 ET

Pulse Biosciences Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q3 EPS Results.

BenzingaOct 31 14:51 ET

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

BusinesswireOct 31 14:25 ET

Q3 2024 Pulse Biosciences Inc Earnings Call

Yahoo FinanceOct 31 13:58 ET

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript Summary

moomoo AIOct 30 22:05 ET · Conference Call

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsOct 30 21:42 ET

Pulse Biosciences | 10-Q: Q3 2024 Earnings Report

SECOct 30 16:12 ET · Announcements

Express News | Pulse Biosciences Q3 Income From Operations USD -13.655 Million

ReutersOct 30 16:05 ET

Pulse Biosciences 3Q Loss $12.7M >PLSE

Dow JonesOct 30 16:05 ET

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

BusinesswireOct 30 16:02 ET

Express News | Pulse Biosciences Announces Appointment of David Kenigsberg, M.d. as Chief Medical Officer of Electrophysiology

ReutersOct 30 16:02 ET

Pulse Biosciences (PLSE.US) will release its financial report after the market closes on October 30th.

$Pulse Biosciences (PLSE.US)$ will release its financial report after the market closes on October 30. How was its previous performance? In 2024 Q2, revenue was $0.0, net income was -$-11.383 million, and EPS was -$0.2. In 2023 Q3, revenue was $0.0, net income was -$-10.566 million, and EPS was -$0.186832. The above data is based on US GAAP accounting standards. Reminder from Futubull.

Moomoo NewsOct 24 21:00 ET

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

BusinesswireOct 21 08:00 ET

Seborrheic Keratosis Treatment Market Report 2024-2030, Featuring Comprehensive Profiles of Aclaris Therapeutics, Alma Lasers, BIOLASE, BioLineRx, DermBiont, Novartis and Pulse Biosciences

Yahoo FinanceAug 28 04:06 ET

Pulse Biosciences | 10-Q: Q2 2024 Earnings Report

SECAug 19 16:28 ET · Announcements